Clinical validation of stem cell reactivation approach positions Pelage as leader in regenerative medicine and aging

LOS ANGELES—(BUSINESS WIRE)— #HairLoss —Pelage Pharmaceuticals, a clinical-stage regenerative medicine company, today announced positive results from its Phase 2a clinical trial of PP405 — a topical therapy for androgenetic alopecia advancing through the FDA clinical development pathway. PP405 is designed to reactivate dormant hair follicle stem cells, offering a potential first-in-class approach for both men and women experiencing hair loss.